Prevalence of Severe Bleeding in COVID-19 Patients Treated With Higher Than Recommended Thromboprophylaxis Doses

Manuel Monreal2,430 enrolled

Overview

The main objectives are: * To establish the prevalence of major bleeding in patients treated with higher than recommended thromboprophylaxis doses. * To identify variables associated to higher risk of bleeding.

Study Type

OBSERVATIONAL

Enrollment

2,430

Conditions

COVID-19

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * Patients infected with COVID-19 treated with higher than recommended thromboprophylaxis doses. * Admission to hospital. Exclusion Criteria: * Patients treated with ECMO (Extracorporeal membrane oxygenation).

Locations (1)

Manuel Monreal

Badalona, Barcelona, Spain

Outcomes

Primary Outcomes

Bleeding events and complications

Study endpoints are clinically recognized (and objectively confirmed) major and minor bleeding complications, and death.

Time frame: 30 days

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.